Introduction
Type 2 diabetes mellitus (T2DM) is a growing health problem across the world, and the number of diagnosed T2DM cases has increased dramatically over the past few decades. 1 Traditional therapies for T2DM include treatment with insulin, sulfonylureas, metformin, peroxisome proliferator-activated receptor-γ agonists, and α-glucosidase inhibitors, the majority of which are small molecules. Unfortunately, these therapies display limited efficacy and have significant mechanism-based side effects. 2 The use of proteins and peptides as human therapeutics has increased rapidly in recent years, and protein-based products are predicted to represent four of the five top-selling drugs in the global market over the next few years. 3, 4 This article was published in the following Dove Press journal: International Journal of Nanomedicine 17 October 2014 Number of times this article has been viewed International Journal of Nanomedicine 2014:9 submit your manuscript | www.dovepress.com
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rao et al BAY 55-9837, a potential protein therapeutic for the treatment of T2DM, was originally engineered by performing iterative rounds of site-directed mutagenesis on vasoactive intestinal peptide (VIP) and pituitary adenylate cyclaseactivating peptide (PACAP). 5 PACAP is a member of the VIP-glucagon-growth hormone-releasing factor secretin superfamily. 6 PACAP exists in two molecular forms: PAC-AP-27 and PACAP-38. 7 PACAP-27 activates both VPAC 1 and VPAC 2 receptors; VPAC 2 activation promotes insulin secretion, whereas VPAC 1 activation enhances glucagon secretion. 8, 9 Both VPAC 1 and VPAC 2 receptors are expressed within islet cells. 10 As such, BAY 55-9837 was engineered to be a potent and highly selective VPAC 2 agonist that can stimulate insulin secretion without stimulating glucagon secretion. 11 Unfortunately, the potential therapeutic benefit of using BAY 55-9837 is limited by its very short half-life in vivo, which is likely due to the rapid renal clearance of the peptide. 12 Therefore, it requires continuous intravenous or subcutaneous infusion to establish efficacy. Recent attempts have been made to overcome these limitations, eg, amino acid substitutions and polyethylene glycolation were used to prolong the half-life of BAY 55-9837 in vivo. 13 The in vivo half-life of protein-based products significantly affects both dosing requirements and therapeutic efficacy; therefore, strategies to prolong the half-life of such drugs are highly significant. One such strategy, which utilizes the polyethylene glycolation of a given therapeutic protein, works to prolong the protein half-life by increasing the apparent size of the polypeptide.
14 Generally, the conjugation of a given therapeutic protein to polymers or the incorporation of it into a drug carrier for protection and slow release is a commonly utilized method of prolonging their in vivo half-life. 15, 16 The emergence of nanostructured biomaterials has enabled new prospects for drug therapies in T2DM. Hybrid organic-inorganic nanoparticles (NPs) possess promising and highly controllable properties that have broad application in drug therapies, including targetable drug delivery. 17 For example, Liu et al 18 demonstrated that the conjugation of selenium NPs (SeNPs) and 5-fluorouracil can achieve anticancer synergism, while Makhluf et al 19 showed that modified polyvinyl alcohol-Fe 3 O 4 NPs can successfully serve as protein carriers that are targetable to sperm cells. Furthermore, it has been found that the half-life of some therapeutics can be improved by conjugating them to nanocarriers. For instance, Singh et al 20 reported that nanocarriers may facilitate the prolonged ductal retention of diagnostic or therapeutic agents. Moreover, Lee et al 21 demonstrated that chitosan (CS)-coated poly(lactic-co-glycolic acid) NPs containing palmitic acidmodified exendin-4 have considerable potential as a longacting inhalation delivery system for the treatment of T2DM. As nanotechnology is widely used in drug therapies, we aimed to design a nanostructure-based medicine system to improve the life span of the low-molecular-weight protein therapeutic BAY 55-9837 by using SeNPs as carriers. Selenate, an essential mineral, is an important component of optimal human health. 22 Recently, SeNPs have been widely studied because of their excellent photoelectric performance and advanced biological activity. 23, 24 Se possesses many beneficial properties, including antioxidant, antiapoptotic, anticancer, and immune-system enhancements. [25] [26] [27] However, its beneficial properties occur within a limited range. In comparison with Se, SeNPs possess lower toxicity as chemotherapeutic agents. 28, 29 Moreover, the mean serum Se concentrations in patients with DM are significantly lower than normal. 30, 31 Owing to their high bioavailability, low toxicity, and novel therapeutic properties, SeNPs have been recognized as a promising tool for drug therapies in T2DM.
CS is an effective and naturally occurring material used for synthesizing NPs with therapeutically desirable properties, such as biocompatibility. Furthermore, CS can be used to modify and stabilize the synthesis of SeNPs. 32 CS NPs have been widely investigated as carriers for therapeutic proteins and genes in recent years. Moreover, positively charged SeNPs can be constructed with a CS-surface decoration, forming a self-assembled layer, which has a significant impact on their performance in biological applications. 33 For these reasons discussed, we utilized CS-SeNPs as nanocarriers to increase the apparent molecular size of BAY 55-9837. As the increased apparent molecular size of BAY 55-9837 can reduce the rate of its renal clearance, BAY-CS-SeNPs may yield longer half-lives in vivo relative to unconjugated BAY 55-9837. 
Materials and methods Materials
Preparation of BaY-cs-seNPs
SeNPs modified by CS were synthesized according to the method of Yu et al 33 by using CS at a concentration of 0.8 mg/mL SeNPs; the concentrations were measured by inductively coupled plasma atomic emission spectrometry. A stock solution of 4 mg/mL BAY 55-9837 was prepared by dissolving 2 mg of BAY 55-9837 powder in 0.5 mL of Milli-Q water. An 8 μL aliquot of a BAY 55-9837 stock solution was mixed with a 24 μL aliquot of CS-SeNPs (0.04368 mg/mL); following this, a 32 μL aliquot of Milli-Q water was added overnight.
Morphology and characterization of BaY-cs-seNPs
BAY-CS-SeNPs and CS-SeNPs were characterized by transmission electron microscopy and scanning electron microscopy (SEM). Energy dispersive X-ray (EDX) spectrometry was employed to analyze the elemental composition of BAY-CS-SeNPs. Samples were freeze-dried prior to characterization by SEM and EDX spectrometry. To measure zeta potential and size distribution, a Zetasizer Nano (Malvern Instruments, Malvern, UK) was used. The structure of BAY-CS-SeNPs was analyzed and characterized by Fourier-transform infrared spectroscopy (FT-IR). FT-IR spectra of the samples were recorded on an Equinox 55 IR spectrometer in the range 4,000-400 cm -1 using the KBr-disk method. The stability of BAY-CS-SeNPs over 42 days was monitored using the Zetasizer Nano. Changes in the size distribution were used to evaluate stability.
evaluation of the loading rate and release process
The quantity of free BAY 55-9837 was determined using a combined ultrafiltration-centrifugation technique. Briefly, 2 mL of BAY-CS-SeNPs was added to Ultrafree ® -MC (50 kD; Millipore, Bedford, MA, USA) and centrifuged for 15 minutes at 5,000 rpm. The filtrates were collected and immediately measured for protein content using a bicinchoninic acid assay. The loading rate of SeNPs was calculated using the following equation: loading rate = (total amount of BAY 55-9837 -the amount of BAY 55-9837 in the filtrate)/ total amount of SeNPs.
To study protein-release behavior in vitro, BAY-CSSeNPs (50 μg/mL) were incubated in RPMI 1640 medium (pH 7.4) with 10% fetal bovine serum at 37°C under constant shaking. At appropriate intervals, samples (50 μL) were removed from the vial using a pipette. The amount of BAY 55-9837 was evaluated using an Agilent HPLC system, and the detection wavelength was set at 280 nm.
Pharmacokinetic studies of BaY 55-9837 and BaY-cs-seNPs in mice hPlc instrumentation and conditions HPLC analysis was carried out on a Waters Alliance 2695-2487 HPLC system fitted with an Agilent C18 column (Waters, Milford, MA, USA). The components were eluted in gradient mode at a flow rate of 1 mL/min. Chromatography was performed at 40°C with mobile phase A H 2 O (0.1% TFA) and mobile phase-B CH 3 CN (0.1% TFA). The gradient of eluent B was as follows: 0-8 minutes, 5%; 8-10 minutes, 5%-25%; 10-15 minutes, 25%-75%; 15-20 minutes, 75%-95%; 20-30 minutes, 95%-5%. The effluent was detected at 280 nm, and the raw data were analyzed by Empower software.
Method validation
Samples for the calibration curve were prepared by combining 20 μL aliquots of mouse plasma with various amounts of BAY 55-9837 (25, 12.5, 3.125, 1.5625, 0.78125, 0.390625, and 0.195313 μg/mL) and a constant amount of internal standard. The peak area ratios of the BAY 55-9837 and internal standard peaks versus the concentration were calculated by least squares linear regression using a weighting factor of 1/x 2 (the reciprocal of the squared concentration). The correlation coefficient was used to evaluate the linearity. The calibration curve was obtained in the concentration range of 0.195313-25 μg/mL in mouse plasma, covering the entire range of the expected concentrations.
Accuracy and precision were determined by interday and intraday assays. The accuracy of the method was evaluated by the comparison of the three nominal concentrations with the corresponding mean calculated concentrations. The interday-precision values were determined in triplicate for BAY 55-9837 at concentrations of 0.195313, 0.78125, and 12.5 μg/mL in mouse plasma. The intraday precision was determined across the same three concentrations on different days. Relative standard deviation (RSD) was calculated to evaluate the precision. The recovery of BAY 55-9837 from the extraction procedure was evaluated at concentrations of 0.195313, 0.78125, and 12.5 μg/mL by comparing the peak area ratios of samples subjected to a solid-phase 
Pharmacokinetic studies
Kunming mice (10 weeks old, 18-22 g) were obtained from the Sun Yat-Sen University Animal Studies Committee. All of the animal experiments were conducted in accordance with the guidelines established by the Jinan University Animal Studies Committee. The mice were randomly divided into two groups of six mice each: group I was administered BAY 55-9837 at a dose of 5 mg/kg; group II was administered BAY-CS-SeNPs in accord with the concentration of BAY 55-9837 in group I. Compounds were delivered via a tail-vein injection. At different time intervals postinjection, 20 μL blood samples were collected from the tail vein in heparinized micropipettes and rapidly mixed with 2 mL of phosphate-buffered saline. The collected samples were centrifuged at 10,000 rpm for 10 minutes, and the supernatants were carefully transferred to the SPE column to remove impurities, such as saline ions. The SPE column was used in accordance with manufacturer instructions. Following pretreatment on the SPE column, the eluent was then concentrated using a Termovap sample concentrator (Organomation, South Berlin, MA, USA). Finally, the residues were dissolved in acetonitrile (20 μL, 50%) containing 0.1% (v/v) TFA, and 10 μL of the sample was applied to the HPLC system for protein-content analysis using the validated method. Thereafter, the data analysis of relevant pharmacokinetic parameters (half-life, area under the curve from time 0 to last sampling point, observed clearance) of BAY 55-9837 was processed by the PKSolver software using noncompartmental analysis. 34 The data are presented as mean values, with the error depicted as the standard deviation. Data were compared using analyses of variance and Student's t-test, and P0.05 was considered significant.
Results and discussion
Morphology and characterization
Transmission electron microscopy and SEM images of CSSeNPs in the absence and presence of BAY 55-9837 are depicted in Figure 1 and Figure 2 , respectively. Figure 1A shows that SeNPs modified by CS were well dispersed, with an average diameter of approximately 70 nm, which can be attributed to the hydroxyl groups in CS, as the hydroxyl groups in CS can react with SeO 3 2-groups to form stable intermediates. 33 BAY-CS-SeNPs presented as homogeneous and spherical, with diameters of approximately 200 nm ( Figure 1 , B and C). BAY-CS-SeNPs were further characterized by SEM and EDX spectroscopy. SEM images of the freeze-dried samples indicated that the morphological characteristics of CS-SeNPs were significantly altered in the presence of BAY 55-9837, demonstrating that BAY 55-9837 was well conjugated to the surface of CS-SeNPs (Figure 2, A and B) . Additionally, the elemental analysis of the EDX spectrum identified the presence of a weak peak from an O atom (7.35%) together with a C-atom peak (17.11%) and a sharp peak of SeNPs (75.54%) from BAY-CS-SeNPs ( Figure 2C ), further confirming the existence of BAY 55-9837.
evaluation of BaY-cs-seNP surface chemistry
The zeta potential of SeNPs was measured at -3.6 mV and increased to 24.8 mV following modification with CS. BAY 55-9837, a 27-amino acid-long polypeptide, is negatively charged under neutral conditions. Following the 
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seNPs as carriers to improve BaY 55-9837 half-life attachment of BAY 55-9837 onto the CS-SeNP surface, the zeta potential decreased to -13.8 mV, which confirmed the existence of BAY 55-9837 ( Figure 3A) . Figure 3B shows the FT-IR spectra analysis of CS-SeNPs, BAY 55-9837, and BAY-CS-SeNPs. The characteristic peaks of CS-SeNPs were in perfect accordance with the study of Yu et al. 33 The peak of BAY 55-9837 at 3,305 cm -1 was attributed to O-H groups, and the peaks at 2,922 cm -1 and 1,660 cm -1 corresponded to C-H and CO-NH, respectively. Characteristic peaks of BAY-CS-SeNPs were consistent with that of BAY 55-9837, except for O-H groups. The characteristic O-H group peak in BAY-CS-SeNPs at 3,431 cm -1 was relatively higher than that of BAY 55-9837. The slight shift of the O-H group was likely caused by the conjugation of BAY 55-9837 to the CS-SeNP surface. In conclusion, the electrostatic force was clearly found to be the main driving force behind protein attachment, while chemical bond changes also occurred during the process of conjugation.
evaluation of BaY-cs-seNP stability
As depicted in Figure 4A , the average diameter of BAY-CSSeNPs was approximately 200 nm. The results show that the size of BAY-CS-SeNPs remained stable during the first few days after formation and then demonstrated a gradual decline, while precipitation was barely observed. Nevertheless, BAY-CS-SeNP size increased dramatically on the 37th day after formation ( Figure 4B ). The gradually declining diameter of the BAY-CS-SeNPs was likely caused by the degradation or release of their surface-layer proteins. At 37 days, the aggregation of SeNPs most likely began to occur, resulting in a radical increase of BAY-CS-SeNP size. The high stability of BAY-CS-SeNPs provides support for translating these findings into future medical applications. 
Loading rate and release profile
The protein-loading rate of CS-SeNPs was detected up to 10.79 mg/mg, revealing that CS-SeNPs possessed a high loading capacity. Se displayed a narrow margin between beneficial and toxic effects. The high loading rate of CS-SeNPs can decrease the dose of CS-SeNPs, which minimizes potential side effects. Furthermore, a low dose of SeNPs may be beneficial in the treatment of T2DM. More importantly, SeNPs displayed excellent antioxidant activity, which may prevent pancreatic β-cells from undergoing apoptosis. Nevertheless, the mechanism by which SeNPs function requires further investigation.
Release rates have an impact on pharmacokinetics, biodistribution, therapeutic activity, toxicity, and drug leakage, and sustained release generally confers better therapeutic activity.
36 Figure 5 shows the release profiles of BAY 55-9837 from the NPs into the medium. The dissociation of BAY 55-9837 from the nanocomposite was clearly observed within the first 12 hours, and reached 49.2%. Following this, BAY 55-9837 released gradually, with cumulative release reaching 78.9% after 72 hours' incubation. Protein release was barely observed thereafter. It took over 70 hours for complete release to occur, without a marked burst release. The rapid release observed during the first 12 hours was most likely due to the weak adsorption of the outer-layer protein, whereas the slower release at later time points may be attributed to the stable interaction induced by chemical bonding and 
4825
seNPs as carriers to improve BaY 55-9837 half-life the strong electrostatic force. Generally, the human body requires higher insulin levels to overcome postmeal rises in glucose so that its level is kept constant in the blood. BAY 55-9837 induces glucose-dependent insulin secretion, so its rapid release during the first 10 hours may provide enough BAY 55-9837 to promote postmeal insulin secretion during the day. As overnight fasting lowers blood glucose levels, the sustained release measured for BAY 55-9837 may also satisfy insulin needs in the evening. Based on the excellent protein-loading capacity of CSSeNPs and the sustained-release profile, BAY-CS-SeNPs can be considered a promising therapeutic with desirable biological properties.
Pharmacokinetic studies of BaY 55-9837 and BaY-cs-seNPs in mice hPlc assay validation BAY 55-9837 and quantitation of substance TP-5 were baseline-separated with retention times of 18.5 and 9.5 minutes without interference from the plasma (Figure 6 ). Pharmacokinetic studies Figure 8 shows the plasma concentration-time profiles of BAY 55-9837 and BAY-CS-SeNPs. BAY 55-9837 exhibited a short life span, which is consistent with the previous study. However, when conjugated to CS-SeNPs, BAY 55-9837 was detectable for up to 70 hours. The corresponding pharmacokinetic parameters are summarized in increased apparent size of BAY 55-9837, indicating that the prolonged plasma persistence and decreased kidney clearance rate measured for BAY 55-9837 followed typical size-related effects. 14 The prolonged in vivo half-life increased the acting time of BAY 55-9837, which would most likely improve insulin secretion.
Conclusion
In summary, our work provides a simple method of extending the half-life of BAY 55-9837 in vivo by conjugating it to CS-SeNPs. BAY-CS-SeNPs possessed a desirable sustained-release profile and demonstrated high stability, with a diameter of approximately 200 nm in vitro. Furthermore, pharmacokinetic quantification revealed that after conjugation to CS-SeNPs, BAY 55-9837 exhibited a lower clearance rate, which resulted in a longer half-life. As illustrated in Figure 9 , we believe that using nanocarrier conjugates can improve the half-life of low-molecular-weight therapeutics by increasing their apparent molecular size. Generally speaking, therapeutics with increased apparent molecular sizes possess lower rates of renal elimination. Furthermore, as carriers, SeNPs themselves may be beneficial in the treatment of T2DM, although a further understanding of the molecular mechanisms underlying this function is still in need of evaluation. The work presented here offers a new pathway forward toward improving the half-life of low-molecular-weight therapeutics in vivo by using nanotechnology. The International Journal of Nanomedicine is an international, peerreviewed journal focusing on the application of nanotechnology in diagnostics, therapeutics, and drug delivery systems throughout the biomedical field. This journal is indexed on PubMed Central, MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine, Journal Citation Reports/Science Edition, EMBase, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/ testimonials.php to read real quotes from published authors.
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